Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Fuji
Teva
US Department of Justice
UBS
Moodys
Covington
Boehringer Ingelheim
Queensland Health

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020717

« Back to Dashboard

NDA 020717 describes PROVIGIL, which is a drug marketed by Cephalon and is included in one NDA. It is available from twelve suppliers. There is one patent protecting this drug. Additional details are available on the PROVIGIL profile page.

The generic ingredient in PROVIGIL is modafinil. There are twenty-six drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the modafinil profile page.
Summary for 020717
Tradename:PROVIGIL
Applicant:Cephalon
Ingredient:modafinil
Patents:1
Therapeutic Class:Central Nervous System Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020717
Suppliers and Packaging for NDA: 020717
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PROVIGIL modafinil TABLET;ORAL 020717 NDA Rebel Distributors Corp 21695-234 21695-234-15 15 TABLET in 1 BOTTLE (21695-234-15)
PROVIGIL modafinil TABLET;ORAL 020717 NDA Rebel Distributors Corp 21695-234 21695-234-30 30 TABLET in 1 BOTTLE (21695-234-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Dec 24, 1998TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:May 29, 2024Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength200MG
Approval Date:Dec 24, 1998TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:May 29, 2024Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 020717

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 ➤ Subscribe ➤ Subscribe
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 ➤ Subscribe ➤ Subscribe
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 ➤ Subscribe ➤ Subscribe
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 ➤ Subscribe ➤ Subscribe
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 ➤ Subscribe ➤ Subscribe
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 ➤ Subscribe ➤ Subscribe
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-001 Dec 24, 1998 ➤ Subscribe ➤ Subscribe
Cephalon PROVIGIL modafinil TABLET;ORAL 020717-002 Dec 24, 1998 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Baxter
Colorcon
Harvard Business School
US Army
Teva
Farmers Insurance
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot